Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: April 2025
Date Filed: April 7, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves as a procedural filing to incorporate exhibits by reference into existing registration statements (Forms S-8 and F-3) and does not contain a financial results table or narrative.
Material Changes
No material changes to financial position or operations are disclosed in this specific filing text. The document primarily lists the submission of Exhibit 99.1, an "Application for quotation of securities."
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, risk factors, or details on contingencies. The document is limited to the cover page and signature block required for the incorporation of exhibits.
Investor Verification Checklist
- Verify the details of the "Application for quotation of securities" referenced as Exhibit 99.1, as the content of this exhibit is not included in the provided text.
- Confirm the status of the referenced Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
- Review the company's most recent Form 20-F or quarterly reports for actual financial performance data, as this filing contains none.